Zevra Therapeutics 관리
관리 기준 확인 0/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Neil McFarlane
최고 경영자
US$3.4m
총 보상
| CEO 급여 비율 | 4.6% |
| CEO 임기 | 1.1yrs |
| CEO 소유권 | n/a |
| 경영진 평균 재임 기간 | 1.8yrs |
| 이사회 평균 재임 기간 | 1.6yrs |
최근 관리 업데이트
Recent updates
Here's What Analysts Are Forecasting For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) After Its Third-Quarter Results
Nov 15
Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects As Shares Rocket 34%
Aug 30Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Jul 12Analysts Just Shaved Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts Dramatically
Apr 07Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Just Reported And Analysts Have Been Cutting Their Estimates
Apr 04Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Apr 02Investors Appear Satisfied With Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) Prospects
Dec 28Bullish: Analysts Just Made A Noticeable Upgrade To Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Forecasts
Sep 05This Just In: Analysts Are Boosting Their Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Outlook for This Year
Aug 20Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stocks Shoot Up 31% But Its P/S Still Looks Reasonable
Apr 17US$18.00: That's What Analysts Think Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Is Worth After Its Latest Results
Mar 10Is Zevra Therapeutics (NASDAQ:ZVRA) Using Debt In A Risky Way?
Mar 08Bearish: Analysts Just Cut Their KemPharm, Inc. (NASDAQ:KMPH) Revenue and EPS estimates
Nov 16Does KemPharm (NASDAQ:KMPH) Have A Healthy Balance Sheet?
Nov 11KemPharm posts Phase 1 data to support further studies for sleep disorder therapy
Sep 28KemPharm wins Buy rating at Canaccord on CNS focus
Sep 15CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$90m |
| Jun 30 2024 | n/a | n/a | -US$67m |
| Mar 31 2024 | n/a | n/a | -US$49m |
| Dec 31 2023 | US$3m | US$158k | -US$46m |
보상 대 시장: Neil 의 총 보상 ($USD 3.45M )은 US 시장( $USD 2.22M ).
보상과 수익: Neil 의 보상을 회사 성과와 비교하기에는 데이터가 부족합니다.
CEO
Neil McFarlane (51 yo)
1.1yrs
테뉴어
US$3,445,231
보상
Mr. Neil F. McFarlane serves as President & Chief Executive Officer at Zevra Therapeutics, Inc. since October 10, 2023 and serves as its Director since October 9, 2023. He served as Independent Director at...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 1.1yrs | US$3.45m | 데이터 없음 | |
| Co-Founder & Chief Development Officer | no data | US$1.67m | 0.051% $ 258.3k | |
| CFO, Secretary & Treasurer | 9.4yrs | US$2.26m | 0.035% $ 175.3k | |
| Chief Commercial Officer & Executive VP of Business Development | 1.8yrs | US$1.82m | 0.0066% $ 33.2k | |
| Chief Scientific Officer | 1.8yrs | US$1.08m | 0.0051% $ 26.0k | |
| Vice President of Investor Relations & Corporate Communications | 2.3yrs | 데이터 없음 | 데이터 없음 | |
| Chief Legal Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief People Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Manufacturing | 1.8yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Clinical Development | 1.8yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Medical Affairs & Advocacy | 1.8yrs | 데이터 없음 | 데이터 없음 | |
| Chief Medical Officer | less than a year | 데이터 없음 | 데이터 없음 |
1.8yrs
평균 재임 기간
52yo
평균 연령
경험이 풍부한 관리: ZVRA 의 관리팀은 경험 (평균 재직 기간 1.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 1.1yrs | US$3.45m | 데이터 없음 | |
| Independent Director | 1.6yrs | US$274.00k | 0% $ 0 | |
| Independent Director | 1.6yrs | US$258.02k | 0% $ 0 | |
| Independent Chair | 3.3yrs | US$324.39k | 0.0014% $ 6.8k | |
| Member of Scientific and Medical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 1.6yrs | US$264.31k | 0.056% $ 284.7k | |
| Independent Director | 1.6yrs | US$260.67k | 0.0028% $ 14.2k | |
| Chairman of Scientific and Medical Advisory Board | 17.8yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific & Medical Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Co-Chair of Physician Advisory Council | 11.1yrs | 데이터 없음 | 데이터 없음 | |
| Co-Chair of Physician Advisory Council | 11.1yrs | 데이터 없음 | 데이터 없음 | |
| Independent Director | 1.3yrs | US$243.04k | 0.037% $ 189.8k |
1.6yrs
평균 재임 기간
58yo
평균 연령
경험이 풍부한 이사회: ZVRA 의 이사회는 경험(평균 재직 기간 1.6 년)으로 간주되지 않으므로 새 이사회가 필요합니다.